182 related articles for article (PubMed ID: 26195509)
1. Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.
Berger KL; Scherer J; Ranga M; Sha N; Stern JO; Quinson AM; Kukolj G
Antimicrob Agents Chemother; 2015 Oct; 59(10):6017-25. PubMed ID: 26195509
[TBL] [Abstract][Full Text] [Related]
2. Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
Berger KL; Sarrazin C; Nelson DR; Scherer J; Sha N; Marquis M; Côté-Martin A; Vinisko R; Stern JO; Mensa FJ; Kukolj G
PLoS One; 2016; 11(8):e0160668. PubMed ID: 27494410
[TBL] [Abstract][Full Text] [Related]
3. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
Berger KL; Triki I; Cartier M; Marquis M; Massariol MJ; Böcher WO; Datsenko Y; Steinmann G; Scherer J; Stern JO; Kukolj G
Antimicrob Agents Chemother; 2014; 58(2):698-705. PubMed ID: 24217701
[TBL] [Abstract][Full Text] [Related]
4. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.
Sulkowski MS; Asselah T; Lalezari J; Ferenci P; Fainboim H; Leggett B; Bessone F; Mauss S; Heo J; Datsenko Y; Stern JO; Kukolj G; Scherer J; Nehmiz G; Steinmann GG; Böcher WO
Hepatology; 2013 Jun; 57(6):2143-54. PubMed ID: 23359516
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection.
Nishiguchi S; Sakai Y; Kuboki M; Tsunematsu S; Urano Y; Sakamoto W; Tsuda Y; Steinmann G; Omata M
Liver Int; 2014 Jan; 34(1):78-88. PubMed ID: 23944720
[TBL] [Abstract][Full Text] [Related]
6. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
Jensen DM; Asselah T; Dieterich D; Foster GR; Sulkowski MS; Zeuzem S; Mantry P; Yoshida EM; Moreno C; Ouzan D; Wright M; Morano LE; Buynak R; Bourlière M; Hassanein T; Nishiguchi S; Kao JH; Omata M; Paik SW; Wong DK; Tam E; Kaita K; Feinman SV; Stern JO; Scherer J; Quinson AM; Voss F; Gallivan JP; Böcher WO; Ferenci P
Ann Hepatol; 2016; 15(3):333-49. PubMed ID: 27049487
[TBL] [Abstract][Full Text] [Related]
7. SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.
Dieterich D; Asselah T; Guyader D; Berg T; Schuchmann M; Mauss S; Ratziu V; Ferenci P; Larrey D; Maieron A; Stern JO; Ozan M; Datsenko Y; Böcher WO; Steinmann G
Antimicrob Agents Chemother; 2014 Jun; 58(6):3429-36. PubMed ID: 24709256
[TBL] [Abstract][Full Text] [Related]
8. Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study.
Berger KL; Lagacé L; Triki I; Cartier M; Marquis M; Lawetz C; Bethell R; Scherer J; Kukolj G
Antimicrob Agents Chemother; 2013 Oct; 57(10):4928-36. PubMed ID: 23877706
[TBL] [Abstract][Full Text] [Related]
9. Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
Dieterich D; Nelson M; Soriano V; Arastéh K; Guardiola JM; Rockstroh JK; Bhagani S; Laguno M; Tural C; Ingiliz P; Jain MK; Stern JO; Manero M; Vinisko R; Kort J;
AIDS; 2015 Mar; 29(5):571-81. PubMed ID: 25710287
[TBL] [Abstract][Full Text] [Related]
10. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.
Lenz O; Verbinnen T; Fevery B; Tambuyzer L; Vijgen L; Peeters M; Buelens A; Ceulemans H; Beumont M; Picchio G; De Meyer S
J Hepatol; 2015 May; 62(5):1008-14. PubMed ID: 25445400
[TBL] [Abstract][Full Text] [Related]
11. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.
Sulkowski MS; Bourlière M; Bronowicki JP; Asselah T; Pawlotsky JM; Shafran SD; Pol S; Mauss S; Larrey D; Datsenko Y; Stern JO; Kukolj G; Scherer J; Nehmiz G; Steinmann GG; Böcher WO
Hepatology; 2013 Jun; 57(6):2155-63. PubMed ID: 23504636
[TBL] [Abstract][Full Text] [Related]
12. Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.
McPhee F; Hernandez D; Zhou N; Ueland J; Yu F; Vellucci V; Huang X; Wang X; Ishikawa H; Karino Y; Kumada H
Antivir Ther; 2018; 23(1):53-66. PubMed ID: 28594332
[TBL] [Abstract][Full Text] [Related]
13. STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
Ferenci P; Asselah T; Foster GR; Zeuzem S; Sarrazin C; Moreno C; Ouzan D; Maevskaya M; Calinas F; Morano LE; Crespo J; Dufour JF; Bourlière M; Agarwal K; Forton D; Schuchmann M; Zehnter E; Nishiguchi S; Omata M; Kukolj G; Datsenko Y; Garcia M; Scherer J; Quinson AM; Stern JO;
J Hepatol; 2015 Jun; 62(6):1246-55. PubMed ID: 25559324
[TBL] [Abstract][Full Text] [Related]
14. Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors.
Kanda T; Yasui S; Nakamura M; Suzuki E; Arai M; Ooka Y; Ogasawara S; Chiba T; Saito T; Haga Y; Takahashi K; Sasaki R; Wu S; Nakamoto S; Tawada A; Maruyama H; Imazeki F; Kato N; Yokosuka O
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28441362
[TBL] [Abstract][Full Text] [Related]
15. Faldaprevir for the treatment of hepatitis C.
Kanda T; Yokosuka O; Omata M
Int J Mol Sci; 2015 Mar; 16(3):4985-96. PubMed ID: 25749475
[TBL] [Abstract][Full Text] [Related]
16. Identification of the NS5B S282T resistant variant and two novel amino acid substitutions that affect replication capacity in hepatitis C virus-infected patients treated with mericitabine and danoprevir.
Tong X; Li L; Haines K; Najera I
Antimicrob Agents Chemother; 2014 Jun; 58(6):3105-14. PubMed ID: 24637689
[TBL] [Abstract][Full Text] [Related]
17. A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.
Zoulim F; Moreno C; Lee SS; Buggisch P; Horban A; Lawitz E; Corbett C; Lenz O; Fevery B; Verbinnen T; Shukla U; Jessner W
Virol J; 2018 Jan; 15(1):26. PubMed ID: 29378602
[TBL] [Abstract][Full Text] [Related]
18. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
McPhee F; Hernandez D; Yu F; Ueland J; Monikowski A; Carifa A; Falk P; Wang C; Fridell R; Eley T; Zhou N; Gardiner D
Hepatology; 2013 Sep; 58(3):902-11. PubMed ID: 23504694
[TBL] [Abstract][Full Text] [Related]
19. Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.
Fevery B; Verbinnen T; Peeters M; Janssen K; Witek J; Jessner W; De Meyer S; Lenz O
J Viral Hepat; 2017 Jan; 24(1):28-36. PubMed ID: 27696653
[TBL] [Abstract][Full Text] [Related]
20. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N
Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
